Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F02%3A00006006" target="_blank" >RIV/65269705:_____/02:00006006 - isvavai.cz</a>
Result on the web
—
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
Concomitant radiotherapy and metronomic temozolomide in pediatric high-risk brain tumors
Original language description
Temozolomide, an oral alkylating agent has a significant activity in preclinical testing and in clinical trials in adults and children as well. Penetration across the blood barrier has been documented. Eight children with poor prognosis brain tumors wereeligible. Treatment consisted from concomitant radiotherapy given 1x170 cGy,5d/wk,for total dose 55/56 Gy, together with temozolomide 90mg/m2/day for 42 days. No further dose escalation has been planneFurthermore, one more patient had CR and 3 patientsPR at the end of temozolomide treatment.We have piloted novel dose schedule of temozolomide and evaluated clinical toxicities in a cohort of 8 children. This is the first study to report feasibility and tolerability of 90mg/m2/day of temozolomide treatment in metronomic fashion. We´ve documented encouraging responses in children with medulloblastomas, progressing early after their initial surgery.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FG - Paediatrics
OECD FORD branch
—

Project
<a href="/en/project/NC7104" target="_blank" >NC7104: Plasma homocysteine and functional activation of p53 as putative markers of effect of high-dose methotrexate in lymphoblastic malignancies in children</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2002
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)